3 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 3 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Chronic Myelogenous Leukemia - Chronic Phase: new trials by email Literature Review of Chronic Myelogenous Leukemia - Chronic Phase trials Research Report on Chronic Myelogenous Leukemia - Chronic Phase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients TGRX-678, TKI - Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Not yet recruiting | Shenzhen TargetRx Co., Ltd. | 180 | 2026-04-01 | 2026-03-24 |
| A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy TKIs - Chronic Myelogenous Leukemia - Chronic Phase | Recruiting | Novartis Pharmaceuticals | 1000 | 2025-12-17 | 2026-07-20 | |
| Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia APN and medical management, Medical management, Quality of life assessment - Chronic Myelogenous Leukemia - Chronic Phase | Not applicable | Recruiting | Centre Hospitalier Henri Duffaut - Avignon | 60 | 2023-11-29 | 2026-03-04 |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) - Leukemia, Acute Myeloid Leukemia in Remission | Not applicable | Recruiting | Medical College of Wisconsin | 40 | 2023-05-01 | 2026-05-13 |
| Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia asciminib - Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2022-11-11 | 2025-10-14 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation ABL001 - Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Completed | Novartis Pharmaceuticals | 56 | 2021-05-25 | 2025-10-16 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase | Phase 4 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 62 | 2016-05-10 | 2021-06-14 |
| Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Nilotinib - Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2008-10-01 | 2021-08-18 |
Leukemia, Myeloid, Chronic-Phase (9) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (9) · Chronic Disease (9) · Disease Attributes (9) · Hemic and Lymphatic Diseases (9) · Leukemia, Myeloid (9) · Myeloproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Hematologic Diseases (8) · Leukemia (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Immune System Diseases (2) · Immunoproliferative Disorders (2)
asciminib (3) · Dasatinib (2) · nilotinib (2) · Blood Specimen Collection (1) · Cyclophosphamide (1) · Cyclosporine (1) · Imatinib Mesylate (1) · Methotrexate (1) · Mycophenolic Acid (1) · Practice Management, Medical (1) · Tacrolimus (1) · Vorinostat (1) · bosutinib (1)
Novartis Pharmaceuticals (4) · Centre Hospitalier Henri Duffaut - Avignon (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Medical College of Wisconsin (1) · Shenzhen TargetRx Co., Ltd. (1) · University of Michigan Rogel Cancer Center (1)
United States (6) · China (1) · France (1)
Christine Tosello, APN (1) · Sung W Choi, MD, MS (1)
PMID 28042454, PMID 39387441, PMID 42784255
UL1TR002240 (1)